Valneva Trading Down 5.9 % Valneva stock opened at $7.44 on Friday. The stock has a market cap of $604.57 million, a PE ratio of -57.23 and a beta of 1.98. Valneva has a 52 week low of $3.62 and a ...

Valneva stock opened at $7.44 on Wednesday. The business has a fifty day moving average of $5.25 and a two-hundred day moving average of $5.68. The company has a quick ratio of 2.25, a current ...

In a report released on February 18, Justine Telliez from Kepler Capital maintained a Buy rating on Valneva (0OB3 – Research Report), with a price target of €8.10. The company’s shares ...

Ratings for Valneva (NASDAQ:VALN) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings ...

H.C. Wainwright lowered the firm’s price target on Valneva (VALN) to $17 from $18 and keeps a Buy rating on the shares following the Q4 report. The firm cites reduced sales estimates for Ixchiq ...

The Danish company’s chikungunya vaccine, Vimkunya, has now crossed the FDA finish line, heating up the competition with Valneva by countering with a label that covers a broader population.

Valneva has met its revenue growth target for 2024, fending off slower-than-expected sales for the chikungunya vaccine Ixchiq. The French vaccine specialist posted total revenues of €169.6m ($ ...

More information is available at www.valneva.com. This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to business ...

More information is available at www.valneva.com. This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to business partnerships ...